331 related articles for article (PubMed ID: 17220905)
1. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
[TBL] [Abstract][Full Text] [Related]
3. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
4. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Bornhäuser M; Thiede C; Schuler U; Platzbecker U; Freiberg-Richter J; Helwig A; Plettig R; Röllig C; Naumann R; Kroschinsky F; Neubauer A; Ehninger G
Bone Marrow Transplant; 2000 Jul; 26(2):119-25. PubMed ID: 10918420
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
Bone Marrow Transplant; 2001 Aug; 28(3):243-9. PubMed ID: 11535991
[TBL] [Abstract][Full Text] [Related]
6. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
Niiya H; Kanda Y; Saito T; Ohnishi T; Kanai S; Kawano Y; Kamijo K; Iizuka A; Yakushijin K; Ueda K; Chizuka A; Iijima K; Ohnishi M; Nakai K; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Haematologica; 2001 Oct; 86(10):1071-4. PubMed ID: 11602413
[TBL] [Abstract][Full Text] [Related]
7. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
[TBL] [Abstract][Full Text] [Related]
8. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
[TBL] [Abstract][Full Text] [Related]
9. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
Johansson JE; Brune M; Ekman T
Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
[TBL] [Abstract][Full Text] [Related]
10. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine-based conditioning for allogeneic transplantation in adults with sickle cell disease.
van Besien K; Bartholomew A; Stock W; Peace D; Devine S; Sher D; Sosman J; Chen YH; Koshy M; Hoffman R
Bone Marrow Transplant; 2000 Aug; 26(4):445-9. PubMed ID: 10982293
[TBL] [Abstract][Full Text] [Related]
12. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
13. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
[TBL] [Abstract][Full Text] [Related]
14. Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
Platzbecker U; Thiede C; Freiberg-Richter J; Röllig C; Helwig A; Schäkel U; Mohr B; Schaich M; Ehninger G; Bornhäuser M
Bone Marrow Transplant; 2001 Mar; 27(5):543-6. PubMed ID: 11313690
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
[TBL] [Abstract][Full Text] [Related]
16. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
[No Abstract] [Full Text] [Related]
17. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT).
Bacigalupo A
Bone Marrow Transplant; 2002 Feb; 29(3):191-5. PubMed ID: 11859390
[TBL] [Abstract][Full Text] [Related]
18. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
Carella AM; Giralt S; Slavin S
Haematologica; 2000 Mar; 85(3):304-13. PubMed ID: 10702821
[TBL] [Abstract][Full Text] [Related]
19. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Giralt S; Thall PF; Khouri I; Wang X; Braunschweig I; Ippolitti C; Claxton D; Donato M; Bruton J; Cohen A; Davis M; Andersson BS; Anderlini P; Gajewski J; Kornblau S; Andreeff M; Przepiorka D; Ueno NT; Molldrem J; Champlin R
Blood; 2001 Feb; 97(3):631-7. PubMed ID: 11157478
[TBL] [Abstract][Full Text] [Related]
20. [Non-myeloablative stem cell transplant].
Shoji N; Mineishi S
Gan To Kagaku Ryoho; 2000 Jun; 27(6):795-800. PubMed ID: 10897204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
